RxDoctor Payments Data

Jason Wuttke

Child & Adolescent Psychiatry · New Orleans, LANPI 1114942083

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.6% of the total across 589 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. Among child & adolescent psychiatry clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,719in general payments, 2019–2025

Across 589 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Tris Pharma Inc$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Ironshore Pharmaceuticals Inc.$882
  • Corium, LLC$682
  • Supernus Pharmaceuticals, Inc.$676
  • plus $5K from 19 others

What the payments were for

  • Food & beverage$10,680100%
  • Education$390%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,719 in reported general payments places this provider in the 95th percentile of 70 child & adolescent psychiatry providers in Louisiana.

See all child & adolescent psychiatry providers in Louisiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate13$29,275
CaplytaLumateperone Tosylate18$26,182
AuvelityDextromethorphan Hbr/Bupropion11$11,714
Jornay PmMethylphenidate Hcl12$5,321
LamictalLamotrigine12$4,223
Duloxetine Hcl33$1,940
Oxcarbazepine19$1,381
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine37$1,236
Aripiprazole25$1,055
Vilazodone Hcl12$982
Venlafaxine Hcl ErVenlafaxine Hcl39$926
Trazodone Hcl39$518
Clonazepam43$449
Lithium Carbonate ErLithium Carbonate20$324
Zolpidem Tartrate ErZolpidem Tartrate20$286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$559$29,27513 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$617$26,18218 claims
Axsome Therapeutics, Inc.Auvelity$340$11,71411 claims
Ironshore Pharmaceuticals Inc.Jornay Pm$882$5,32112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 70 child & adolescent psychiatry providers in Louisiana.

Other child & adolescent psychiatry in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →